(a) Outcome data of randomized controlled trials of the included studies.
| Study | Year | Implant number | Sinus | Residual bone height (mm) | New bone formation | Residual graft particles | Soft tissue area | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N—PRF | PRF | N—PRF | PRF | N—PRF | PRF | N—PRF | PRF | N—PRF | PRF | N—PRF | PRF | ||
| Nizam N | 2018 | 28 | 30 | 13 | 13 | 2.53±0.61 | 2.45±0.79 | 21.25±5.59% | 21.38± 8.78% | 32.79± 5.89% | 25.95 ±9.54% | 45.96±8.36% | 52.67±12.53% |
|
| |||||||||||||
| Zhang Y | 2012 | Delayed implant placement | 5 | 6 | NA | NA | 12.95±5.33% | 18.35 ± 5.62% | 28.54 ±12.01% | 19.16±6.89% | NA | NA | |
|
| |||||||||||||
| Comert K S | 2017 | Delayed implant placement | 9 | 8 | NA | NA | 33.40±10.43% | 32.03±6.34% | 30.39 ±10.29% | 32.66 ±7.46% | 36.21 ±10.59% | 35.31 ±10.81% | |
|
| |||||||||||||
| Tatullo M | 2012 | Delayed implant placement | 30 | 42 | NA | NA | NA | NA | NA | NA | NA | NA | |
|
| |||||||||||||
| Gurler G | 2016 | Delayed implant placement | 12 | 12 | NA | NA | NA | NA | NA | NA | NA | NA | |
N-PRF: non-platelet-rich fibrin group; PRF: platelet-rich fibrin group; NA: not available. The percentage of newly formed bone (BV/TV); the percentage of residual bone graft (BSV/TV); the percentage of length of the profile of the bone graft in contact with new bone (bone-to-bone graft contact).